These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12882616)

  • 21. [Antiviral treatment of chronic hepatitis C].
    Berger A
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.
    Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ
    Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental therapy in HCV infection].
    Inglot M; Gładysz A; Rymer W
    Przegl Epidemiol; 2005; 59(2):525-33. PubMed ID: 16190563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline.
    Huang M; Deshpande M
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):375-88. PubMed ID: 15482203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Zeuzem S; Nelson DR; Marcellin P
    Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
    Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
    J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

  • 33. The science of direct-acting antiviral and host-targeted agent therapy.
    Pawlotsky JM
    Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents.
    Olsen DB; Davies ME; Handt L; Koeplinger K; Zhang NR; Ludmerer SW; Graham D; Liverton N; MacCoss M; Hazuda D; Carroll SS
    Antimicrob Agents Chemother; 2011 Feb; 55(2):937-9. PubMed ID: 21115793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-nucleoside inhibitors of the HCV polymerase.
    Sarisky RT
    J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease.
    Avolio S; Summa V
    Curr Top Med Chem; 2010; 10(14):1403-22. PubMed ID: 20536420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
    Bachmetov L; Gal-Tanamy M; Shapira A; Vorobeychik M; Giterman-Galam T; Sathiyamoorthy P; Golan-Goldhirsh A; Benhar I; Tur-Kaspa R; Zemel R
    J Viral Hepat; 2012 Feb; 19(2):e81-8. PubMed ID: 22239530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoprotease.
    Shaw J; Fishwick CW; Harris M
    Antiviral Res; 2015 May; 117():20-6. PubMed ID: 25703928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.